Overview
Leydig cell agenesis refers to the absence or dysfunction of Leydig cells in the testes, leading to impaired testosterone production and potential reproductive and hormonal issues. 1Diagnosis
LHRH Stimulation Test: Identifies Leydig cell dysfunction by measuring serum testosterone response 1.
Semen Analysis: Evaluates sperm parameters including density, motility, and morphology 1.
Serum Hormone Levels: Measures testosterone and other relevant hormones to assess hypogonadism 1.Management
Human Chorionic Gonadotropin (hCG):
- Dose: 50,000 units in 10 divided doses intramuscularly over 10 weeks.
- Indication: For patients with persistent Leydig cell dysfunction post-varicocelectomy.
- Outcome: Improves sperm parameters and testosterone levels, enhancing fertility 1.
o,p'-DDD:
- Indication: Used in treating metastatic Leydig cell carcinoma, showing objective clinical remission in some cases 2.Special Populations
Post-Varicocelectomy Patients: hCG therapy recommended for those with sustained Leydig cell dysfunction 1.Key Recommendations
Administer hCG (50,000 units in 10 divided doses intramuscularly over 10 weeks) to patients with persistent Leydig cell dysfunction following varicocelectomy to improve fertility outcomes (Evidence: Moderate 1).
Consider o,p'-DDD as a potential therapeutic agent for patients with metastatic Leydig cell carcinoma, given its reported efficacy in achieving clinical remission (Evidence: Weak 2).
Regular follow-up with semen analysis and serum hormone levels is essential to monitor treatment efficacy in Leydig cell dysfunction (Evidence: Expert opinion).References
1 Yamamoto M, Hibi H, Katsuno S, Miyake K. Human chorionic gonadotropin adjuvant therapy for patients with Leydig cell dysfunction after varicocelectomy. Archives of andrology 1995. link
2 Azer PC, Braunstein GD. Malignant Leydig cell tumor: objective tumor response to o,p'-DDD. Cancer 1981. link47:6<1251::aid-cncr2820470604>3.0.co;2-r)